Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

Recent & Breaking News (TSXV:XRTX)

IIROC Trading Halt - XRX

Canada NewsWire October 8, 2020

XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

GlobeNewswire October 8, 2020

XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection

GlobeNewswire September 15, 2020

XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission

GlobeNewswire August 31, 2020

XORTX Announces Change to Board of Directors

GlobeNewswire August 28, 2020

An Intriguing Post-COVID-19 Bio-Pharma Opportunity

Dave Jackson August 20, 2020

XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries

Livemoney August 19, 2020

XORTX Appoints Dr. David Sans in New York as Director Corporate Development

GlobeNewswire August 7, 2020

IIROC Trade Resumption - XRX

Canada NewsWire August 4, 2020

XORTX Partners with Mount Sinai's Icahn School of Medicine on US-based Clinical Trial in COVID-19

GlobeNewswire August 4, 2020

IIROC Trading Halt - XRX

Canada NewsWire August 4, 2020

XORTX Announces Mr. Anthony J. Giovinazzo to Join as Special Advisor to the Board of Directors

GlobeNewswire June 23, 2020

Relief for the COVID Kidney Threat?

Stockhouse Editorial May 21, 2020

XORTX Provides Program Update Regarding XRx-008 for ADPKD and XRx-101 for Coronavirus / COVID-19 Programs

GlobeNewswire May 19, 2020

Biopharma Co. Reports 1st Step to Advance Clinical COVID Treatment Trials

Stockhouse Editorial May 4, 2020

XORTX Highlights Recent Business & Medical Milestones

Stockhouse Editorial May 1, 2020

IIROC Trade Resumption - XRX

Canada NewsWire April 30, 2020

XORTX Appoints Lonza for GMP Manufacturing and Formulation of XRx-101 (Oxypurinol) for Coronavirus / COVID-19 Clinical Trials

GlobeNewswire April 30, 2020

IIROC Trading Halt - XRX

Canada NewsWire April 30, 2020

XORTX Provides Overview and Update of Key Activities

GlobeNewswire April 30, 2020